Sex-Specific Expression of Histone Lysine Demethylases (KDMs) in Thyroid Cancer.

KDMs histone lysine demethylases sex difference thyroid cancer

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
23 Mar 2024
Historique:
received: 03 03 2024
revised: 18 03 2024
accepted: 19 03 2024
medline: 13 4 2024
pubmed: 13 4 2024
entrez: 13 4 2024
Statut: epublish

Résumé

The incidence of thyroid cancer in women is 3-4-fold higher than in men. To characterize sex-specific molecular alterations in thyroid cancer, we examined the expression of sex-biased genes in normal thyroids and thyroid tumors. Ingenuity pathways analysis was used to define sex-biased gene networks using data from the Cancer Genome Atlas (TCGA). Confirmatory studies were performed through the analysis of histone lysine demethylases (KDMs) expression by real-time PCR and immunostaining. In normal thyroids, 44 sex-biased genes were comparatively upregulated in male and 28 in female patients. The expressions of 37/72 (51%) sex-biased genes were affected in cancer tissues compared with normal thyroids. Gene network analyses revealed sex-specific patterns in the expressions of KDM5C, KDM5D, and KDM6A. In confirmatory studies, KDM5D mRNA and protein were detected only in males, whereas KDM5C and KDM6A were detected in samples from male and female patients. Nuclear staining with anti-KDMs was found in normal thyroids, but a loss of nuclear expression with a concomitant gain of cytoplasmic staining was observed in cancer tissues. Normal thyroids have a sex-specific molecular signature, and the development of thyroid cancer is associated with a differential expression of sex-biased genes. The sex-specific expression of KDMs, coupled with cancer-related alterations in their intracellular localization, may contribute to mechanisms underlying sex differences in thyroid tumorigenesis.

Sections du résumé

BACKGROUND BACKGROUND
The incidence of thyroid cancer in women is 3-4-fold higher than in men. To characterize sex-specific molecular alterations in thyroid cancer, we examined the expression of sex-biased genes in normal thyroids and thyroid tumors.
METHODS METHODS
Ingenuity pathways analysis was used to define sex-biased gene networks using data from the Cancer Genome Atlas (TCGA). Confirmatory studies were performed through the analysis of histone lysine demethylases (KDMs) expression by real-time PCR and immunostaining.
RESULTS RESULTS
In normal thyroids, 44 sex-biased genes were comparatively upregulated in male and 28 in female patients. The expressions of 37/72 (51%) sex-biased genes were affected in cancer tissues compared with normal thyroids. Gene network analyses revealed sex-specific patterns in the expressions of KDM5C, KDM5D, and KDM6A. In confirmatory studies, KDM5D mRNA and protein were detected only in males, whereas KDM5C and KDM6A were detected in samples from male and female patients. Nuclear staining with anti-KDMs was found in normal thyroids, but a loss of nuclear expression with a concomitant gain of cytoplasmic staining was observed in cancer tissues.
CONCLUSIONS CONCLUSIONS
Normal thyroids have a sex-specific molecular signature, and the development of thyroid cancer is associated with a differential expression of sex-biased genes. The sex-specific expression of KDMs, coupled with cancer-related alterations in their intracellular localization, may contribute to mechanisms underlying sex differences in thyroid tumorigenesis.

Identifiants

pubmed: 38610938
pii: cancers16071260
doi: 10.3390/cancers16071260
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Leila Shobab (L)

Department of Medicine, Division of Endocrinology, MedStar Washington Hospital Center, Washington, DC 20010, USA.

Hui Zheng (H)

Department of Surgery, MedStar Washington Hospital Center, Washington, DC 20010, USA.

Kirk Jensen (K)

Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.

Maria Cecilia Mendonca-Torres (MC)

Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.

Matthew McCoy (M)

Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington, DC 20007, USA.

Victoria Hoperia (V)

Institute of Biology and Medicine, Kyiv National University, 02000 Kyiv, Ukraine.

Jennifer Rosen (J)

Department of Surgery, MedStar Washington Hospital Center, Washington, DC 20010, USA.

Leonard Wartofsky (L)

Department of Medicine, Division of Endocrinology, MedStar Washington Hospital Center, Washington, DC 20010, USA.

Kenneth Burman (K)

Department of Medicine, Division of Endocrinology, MedStar Washington Hospital Center, Washington, DC 20010, USA.

Vasyl Vasko (V)

Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.

Classifications MeSH